Effect of Liberal and Restrictive Fluids on Nausea-vomiting
NCT ID: NCT06197659
Last Updated: 2024-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
160 participants
INTERVENTIONAL
2024-01-01
2024-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of High Intraoperative Fraction of Inspired Oxygen in Preventing Postoperative Nausea and Vomiting
NCT06390280
Preoperative Intravenous Fluid Type and Postoperative Nausea
NCT05961722
Low-pressure vs Standard-pressure in Laparoscopic Cholecystectomy
NCT04146090
Clinical Impact of Routine Abdominal Drainage After Laparoscopic Cholecystectomy
NCT00886210
Cold Application Effects on Nausea and Vomiting After Laparoscopic Cholecystectomy
NCT06008262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Since most existing antiemetics are expensive and cannot completely eliminate PONV, pharmacological PONV prophylaxis may not be cost-effective. For this reason, the incidence of PONV can be reduced by increasing the amount of inexpensive fluid used during surgery instead of prophylactic drug treatment. There are several studies investigating the effect of different perioperative fluid administration schemes on PONV in the adult population, especially in patients undergoing laparoscopic cholecystectomy or gynecological surgery, with variable results.
Based on this point, the inestigetors wanted to examine the effect of perioperative liberal and restrictive fluid treatments on PONV in patients who underwent laparoscopic cholecystectomy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
1. Experimental Group: Group L; Liberal Fluid Group; Peroperative 20 mL/kg/h intravenous ringer lactate will be administered.
2. Sham Comparator: Group R; Restrictive Fluid Group; Peroperative 5 mL/kg/h intravenous ringer lactate will be administered.
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liberal Fluid Group
Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
Liberal Fluid Grubu
Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
Restrictive Fluid Group
Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
Restrictive Fluid Group
Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Liberal Fluid Grubu
Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.
Restrictive Fluid Group
Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients aged 18-70
Exclusion Criteria
* Diabetes.
* Epilepsy.
* Heart valve disease.
* They are pregnant.
* Chronic liver disease.
* Chronic kidney disease. Chronic gastrointestinal tract disease. Those who used antiemetic drugs within 24 hours before surgery. Those who developed intraoperative hypertension. Those who develop excessive blood loss. Patients whose surgery procedure takes more than 2 hours.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karaman Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
muhammet korkusuz
Principal Investigator, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muhammet Korkusuz
Role: PRINCIPAL_INVESTIGATOR
Karamanoglu Mehmetbey University, School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karaman Taining and Research Hospital
Karaman, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-2023/14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.